These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38665214)

  • 21. International Conference on Harmonisation; guidance on S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals intended for Human Use; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Jun; 77(110):33748-9. PubMed ID: 22675782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory Forum Opinion Piece: Carcinogen Risk Assessment: The Move from Screens to Science.
    Downes N; Foster J
    Toxicol Pathol; 2015 Dec; 43(8):1064-73. PubMed ID: 26296629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals.
    Contrera JF; Jacobs AC; DeGeorge JJ
    Regul Toxicol Pharmacol; 1997 Apr; 25(2):130-45. PubMed ID: 9185889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving carcinogenicity assessment.
    Morton D; Bourcier T; Alden CL
    Toxicol Pathol; 2013 Feb; 41(2):263-70. PubMed ID: 23076039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How useful are chronic (life-span) toxicology studies in rodents in identifying pharmaceuticals that pose a carcinogenic risk to humans?
    Monro A
    Adverse Drug React Toxicol Rev; 1993; 12(1):5-34. PubMed ID: 8513076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of alternative methods of carcinogenicity testing and evaluation of human pharmaceuticals.
    Van Deun K; Van Cauteren H; Vandenberghe J; Canning M; Vanparys P; Coussement W
    Adverse Drug React Toxicol Rev; 1997 Nov; 16(4):215-33. PubMed ID: 9608857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum.
    Morga A; Latimer NR; Scott M; Hawkins N; Schlichting M; Wang J
    Value Health; 2023 Feb; 26(2):234-242. PubMed ID: 36150999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicology and Carcinogenesis Studies of 5,5-Diphenylhydantoin (CAS No. 57-41-0) (Phenytoin) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Nov; 404():1-303. PubMed ID: 12621514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peer review of a cancer weight of evidence assessment based on updated toxicokinetics, genotoxicity, and carcinogenicity data for 1,3-dichloropropene using a blinded, virtual panel of experts.
    Hays SM; Nelson DM; Kirman CR
    Crit Rev Toxicol; 2020 Nov; 50(10):861-884. PubMed ID: 33528305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose selection for carcinogenicity studies of pharmaceuticals: systemic exposure to phenacetin at carcinogenic dosage in the rat.
    Bergman K; Olofsson I; Sjöberg P
    Regul Toxicol Pharmacol; 1998 Dec; 28(3):226-9. PubMed ID: 10049794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices.
    Bogdanffy MS; Lesniak J; Mangipudy R; Sistare FD; Colman K; Garcia-Tapia D; Monticello T; Blanset D
    Int J Toxicol; 2020; 39(3):198-206. PubMed ID: 32372678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact.
    Müller L; Kikuchi Y; Probst G; Schechtman L; Shimada H; Sofuni T; Tweats D
    Mutat Res; 1999 May; 436(3):195-225. PubMed ID: 10354523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are lifespan rodent carcinogenicity studies defensible for pharmaceutical agents?
    Monro A
    Exp Toxicol Pathol; 1996 Feb; 48(2-3):155-66. PubMed ID: 8672869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The international harmonisation of guidelines in the future: a viewpoint from the industry.
    Ekman L
    Toxicol Lett; 1998 Dec; 102-103():551-5. PubMed ID: 10022311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory Acceptance of Alternative Methods in the Development and Approval of Pharmaceuticals.
    Beken S; Kasper P; van der Laan JW
    Adv Exp Med Biol; 2016; 856():33-64. PubMed ID: 27671719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both?
    Abraham J; Reed T
    Soc Sci Med; 2003 Jul; 57(2):195-204. PubMed ID: 12765701
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of transgenic mice in carcinogenicity hazard assessment.
    Jacobson-Kram D; Sistare FD; Jacobs AC
    Toxicol Pathol; 2004; 32 Suppl 1():49-52. PubMed ID: 15209403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alternatives to Monkey Reproductive Toxicology Testing for Biotherapeutics.
    Hoberman AM; Maki K; Mikashima F; Naota M; Wange RL; Lansita JA; Weis SL
    Int J Toxicol; 2023 Dec; 42(6):467-479. PubMed ID: 37714565
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.